Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Erbach – page 36

675 clinical trials in Erbach, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Erbach at a glance
675
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

675 trials in Erbach

Open in trial search

A Study to Test the Long-term Safety and Benefits of GSK4527226 in Patients with Early Alzheimer's Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:GSK4527226
  • Sponsor:Glaxosmithkline Research & Development Limited

Dermatitis atopic

Not recruiting

Study of Rocatinlimab with Topical Treatments for Adults with Moderate to Severe Atopic Dermatitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Breast cancer+1

Not recruiting

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Major depression

Not recruiting

Study of lavender oil (Silexan) in patients with mild to moderate major depressive disorder comparing its effectiveness to placebo

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lavender Oil
  • Sponsor:Dr. Willmar Schwabe GmbH & Co. KG

Colitis ulcerative

Not recruiting

Study of SAR442970 to treat moderate to severe ulcerative colitis in adults

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:SAR442970
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Colitis ulcerative

Not recruiting

Study of efavaleukin alfa safety and effectiveness in adults with moderate to severe ulcerative colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Colitis ulcerative

Not recruiting

Study of Efavaleukin Alfa to Treat Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Arteriosclerosis

Not recruiting

Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Neoplasm malignant

Not recruiting

Study of S095035 and TNG462 in adults with advanced or metastatic solid tumors with MTAP deletion

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:S095035
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Hidradenitis

Not recruiting

Study of ruxolitinib cream applied to the skin for people with hidradenitis suppurativa

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

Study of ifinatamab deruxtecan alone or in combination with other treatments for patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Merck Sharp & Dohme LLC

Parkinson's disease

Not recruiting

Comparing Skin Adhesiveness of a New Rotigotine 12 mg/24 h Transdermal Patch Versus Standard Treatment in Patients with Parkinson's Disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rotigotine
  • Sponsor:Luye Pharma Switzerland AG

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Erbach

What the registry says about research in the country

01 Alzheimer's Disease Research

Groundbreaking clinical trials focusing on early Alzheimer's disease treatments and interventions for associated psychosis. Studies are evaluating novel compounds for managing cognitive decline and neuropsychiatric symptoms.

  • Early-stage disease intervention
  • Psychosis management
  • Cognitive function preservation

Multiple therapeutic approaches targeting both cognitive symptoms and behavioral manifestations of the disease.

02 Migraine Studies

Innovative research examining new treatments for menstrual migraine and chronic migraine conditions. Comparative studies evaluating the effectiveness of different preventive treatments.

  • Preventive treatment protocols
  • Medication comparison studies
  • Gender-specific approaches

Focus on developing targeted therapies for specific types of migraines and their prevention.

03 Multiple Sclerosis Initiatives

Comprehensive research programs investigating treatments for various forms of multiple sclerosis, including progressive and relapsing forms. Studies utilize advanced imaging techniques to track disease progression.

  • Progressive MS treatments
  • Brain atrophy assessment
  • Disability progression prevention

Advanced therapeutic approaches targeting different disease manifestations and progression patterns.

04 Parkinson's Disease Studies

Innovative research focusing on early-onset Parkinson's disease, examining long-term treatment efficacy and brain pathophysiology changes. Studies aim to understand disease progression and therapeutic interventions.

  • Early intervention strategies
  • Long-term treatment effects
  • Disease modification approaches

Emphasis on understanding disease mechanisms and developing targeted therapeutic solutions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.